SG11201508167PA - Therapeutic compositions and uses thereof - Google Patents

Therapeutic compositions and uses thereof

Info

Publication number
SG11201508167PA
SG11201508167PA SG11201508167PA SG11201508167PA SG11201508167PA SG 11201508167P A SG11201508167P A SG 11201508167PA SG 11201508167P A SG11201508167P A SG 11201508167PA SG 11201508167P A SG11201508167P A SG 11201508167PA SG 11201508167P A SG11201508167P A SG 11201508167PA
Authority
SG
Singapore
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
SG11201508167PA
Other languages
English (en)
Inventor
Darina Lazarova Lazarova
Kerry Paul
Owen Catchpole
Original Assignee
Manuka Health New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manuka Health New Zealand Ltd filed Critical Manuka Health New Zealand Ltd
Publication of SG11201508167PA publication Critical patent/SG11201508167PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • A61K35/644Beeswax; Propolis; Royal jelly; Honey
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Molecular Biology (AREA)
SG11201508167PA 2013-04-05 2014-04-07 Therapeutic compositions and uses thereof SG11201508167PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ60907413 2013-04-05
PCT/NZ2014/000060 WO2014163513A1 (en) 2013-04-05 2014-04-07 Therapeutic compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11201508167PA true SG11201508167PA (en) 2015-10-29

Family

ID=51658696

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508167PA SG11201508167PA (en) 2013-04-05 2014-04-07 Therapeutic compositions and uses thereof

Country Status (12)

Country Link
US (2) US20160051594A1 (enExample)
EP (1) EP2983681B1 (enExample)
JP (1) JP6429859B2 (enExample)
KR (1) KR20160021081A (enExample)
CN (1) CN105307665B (enExample)
AU (1) AU2014250139B2 (enExample)
BR (1) BR112015025025A2 (enExample)
CA (1) CA2908185A1 (enExample)
EA (1) EA201591925A1 (enExample)
SG (1) SG11201508167PA (enExample)
TW (1) TW201532608A (enExample)
WO (1) WO2014163513A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163728B (zh) * 2013-04-05 2018-10-02 蜜纽康新西兰有限公司 包含蜂胶提取物的治疗性组合物和其用途
EP2983681B1 (en) * 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
TW201609113A (zh) * 2014-07-18 2016-03-16 歐文 約翰 蓋奇波 治療組合物及其用途
JP2019515943A (ja) * 2016-03-24 2019-06-13 マヌカ ヘルス ニュージーランド リミテッド 治療用組成物およびその使用
ITUA20163755A1 (it) * 2016-05-24 2017-11-24 Aboca Spa Societa Agricola Composizioni a base di gemme di pioppo e loro usi
CN107194205B (zh) * 2017-05-31 2020-11-24 浙江大学 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法
WO2019226469A1 (en) * 2018-05-19 2019-11-28 Fort Lewis College Chemical compositions for combating honey bee pests and pathogens
RU2697839C1 (ru) * 2018-11-14 2019-08-21 Александр Александрович Кролевец Способ получения нанокапсул сухого экстракта прополиса
JP7166965B2 (ja) * 2019-03-13 2022-11-08 株式会社ファンケル bFGF発現増強用組成物
TR201908777A2 (tr) * 2019-06-13 2019-07-22 Sbs Bilimsel Bio Coezuemler Sanayi Ve Ticaret A S Suda Çözünür ve Suda Çözünür Olmayan Özellikte Yüksek Antioksidan Kapasitesine Sahip Propolis Ürünleri ve Üretim Yöntemi
CA3171585A1 (en) * 2020-03-13 2021-09-16 Alli Murugesan Composition and use of a caffeic acid phenethyl ester (cape) compound to treat cancer
KR102470869B1 (ko) * 2020-12-18 2022-11-29 대한민국 프로테아좀 저해제 및 프로폴리스를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 및 이의 용도
CN117551222A (zh) * 2022-08-04 2024-02-13 中科中山药物创新研究院 大蒜素-环糊精包合物共晶的晶型及其制备方法和应用
CN116492324A (zh) * 2023-01-04 2023-07-28 河南科技大学第一附属医院 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物
WO2024246220A1 (en) * 2023-05-31 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JP3035834B2 (ja) * 1991-04-11 2000-04-24 株式会社林原生物化学研究所 プロポリス成分含有固状物とその製造方法並びに用途
US5561116A (en) * 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
US5922324A (en) 1995-01-31 1999-07-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Propolis extract with improved water-solubility
JP4135816B2 (ja) * 1995-11-24 2008-08-20 株式会社林原生物化学研究所 水溶性を向上させたプロポリス抽出物
CN1241577C (zh) * 2003-03-13 2006-02-15 吉林大学 环糊精衍生物的药物用途及其药物组合物
JP4950682B2 (ja) * 2007-01-30 2012-06-13 アピ株式会社 プロポリス抽出物
GR1007520B (el) * 2010-12-02 2012-02-02 Apivita - Καλλυντικα - Διαιτητικα - Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια, Ταυτοχρονη εκχυλιση και σχηματισμος συμπλοκων εγκλεισμου των δραστικων συστατικων της προπολης με υδροξυπροπυλο-β-κυκλοδεξτρινη
US20130309218A1 (en) * 2011-01-31 2013-11-21 Wacker Chemie Ag Process for producing aqueous solution containing fat-soluble substance
EP2983681B1 (en) * 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
CN105163728B (zh) 2013-04-05 2018-10-02 蜜纽康新西兰有限公司 包含蜂胶提取物的治疗性组合物和其用途

Also Published As

Publication number Publication date
JP2016516751A (ja) 2016-06-09
EA201591925A1 (ru) 2016-02-29
EP2983681A1 (en) 2016-02-17
HK1220920A1 (zh) 2017-05-19
JP6429859B2 (ja) 2018-11-28
US10420804B2 (en) 2019-09-24
US20160051594A1 (en) 2016-02-25
WO2014163513A1 (en) 2014-10-09
TW201532608A (zh) 2015-09-01
KR20160021081A (ko) 2016-02-24
EP2983681B1 (en) 2020-07-15
AU2014250139B2 (en) 2019-09-12
US20170290865A1 (en) 2017-10-12
CA2908185A1 (en) 2014-10-09
EP2983681A4 (en) 2017-01-04
AU2014250139A1 (en) 2015-11-12
CN105307665A (zh) 2016-02-03
BR112015025025A2 (pt) 2017-07-18
CN105307665B (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL286759A (en) Therapeutic methods and preparations
ZA201506487B (en) Therapeutic compounds and compositions
GB2535911B (en) Strigolactone formulations and uses thereof
GB2533892B (en) Compositions and methods
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
IL244850A0 (en) Stabilized epinaconazole preparations, and their uses
GB201317286D0 (en) Composition and Use
EP2989240A4 (en) INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
GB201308072D0 (en) Compositions and methods
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
SG11201508167PA (en) Therapeutic compositions and uses thereof
GB201321693D0 (en) Composition and uses thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en) Compositions and methods
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB2516838B (en) Fungicidal compositions and their use
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201301979D0 (en) New composition and use thereof
GB201305297D0 (en) Novel agents and uses thereof
GB201319255D0 (en) Therapeutic compositions and methods
GB201308242D0 (en) Compositions and uses thereof
GB201301022D0 (en) Composition and uses thereof
GB201322467D0 (en) Composition and use